Structural highlights
4h5n is a 2 chain structure with sequence from Human. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
|
| Ligands: | , , , |
| Related: | 4h5r, 4h5t, 4h5v, 4h5w |
| Gene: | HSC70, HSP73, HSPA10, HSPA8 (HUMAN) |
| Resources: | FirstGlance, OCA, RCSB, PDBsum |
Function
[HSP7C_HUMAN] Acts as a repressor of transcriptional activation. Inhibits the transcriptional coactivator activity of CITED1 on Smad-mediated transcription. Chaperone. Component of the PRP19-CDC5L complex that forms an integral part of the spliceosome and is required for activating pre-mRNA splicing. May have a scaffolding role in the spliceosome assembly as it contacts all other components of the core complex.[1]
Publication Abstract from PubMed
In recent years the chaperone HSC-70 has become a target for drug design with a strong focus in anticancer therapies. In our study of possible inhibitors of HSC-70 enzymatic activity we screened compounds by NMR as well as X-ray crystallography. As part of our screening efforts we crystallized the human HSC-70 ATP binding domain and obtained novel crystal forms in addition to known structures. The new crystal structures highlight the mobility of the entire domain previously described by NMR, which was linked to its chaperone activity but not yet demonstrated by X-ray crystallography. Conformational changes across the entire molecule have been elucidated in response to the binding of small molecule ligands and show a pattern of mobility consistent with postulated signal transduction modes between the nucleotide binding domain (NBD) and the substrate binding domain (SBD). In addition, two crystal structures contained glycerol bound at a new site. Binding studies performed with glycerol analogs proved inhibitory properties of the site, which were further characterized by isothermal calorimetry and in silico docking studies. The presence of two binding pockets enabled us to explore a novel method of inhibition by compounds that bridge the adjacent phosphate and glycerol binding sites. Finally, an example of such a bridged inhibitor is proposed.
New crystal structures of HSC-70 ATP binding domain confirm the role of individual binding pockets and suggests a new method of inhibition.,Zhang Z, Cellitti J, Teriete P, Pellecchia M, Stec B Biochimie. 2014 Nov 27. pii: S0300-9084(14)00353-8. doi:, 10.1016/j.biochi.2014.11.012. PMID:25433210[2]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Yahata T, de Caestecker MP, Lechleider RJ, Andriole S, Roberts AB, Isselbacher KJ, Shioda T. The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors. J Biol Chem. 2000 Mar 24;275(12):8825-34. PMID:10722728
- ↑ Zhang Z, Cellitti J, Teriete P, Pellecchia M, Stec B. New crystal structures of HSC-70 ATP binding domain confirm the role of individual binding pockets and suggests a new method of inhibition. Biochimie. 2014 Nov 27. pii: S0300-9084(14)00353-8. doi:, 10.1016/j.biochi.2014.11.012. PMID:25433210 doi:http://dx.doi.org/10.1016/j.biochi.2014.11.012
